About CuraGen
CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.
Safe Harbor
Statements in this press release regarding management's future
expectations, beliefs, intentions, goals, strategies, plans or prospects,
including statements relating to the Company's future cash and investment
positions, the timing and expected results of our clinical programs, and
the development and marketability of planned drugs, may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be identified
by terminology such as "anticipate," "believe," "could," "could increase
the likelihood," "estimate," "expect," "intend," "is planned," "may,"
"should,"
'/>"/>
| SOURCE CuraGen Corporation Copyright©2007 PR Newswire. All rights reserved |